Mergers & acquisitions
Hong Kong-based Prenetics Group Limited, a medical diagnostic startup, is making its debut on the Nasdaq through a merger with Artisan Acquisitions Corp. The deal is valued at $1.25 billion.
AzurRx will change its name to First Wave BioPharma, Inc., and the company’s shares will trade on the Nasdaq under the ticker symbol “FWBI.”
The procurement will expand its PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new COVID-19 variants of interest.
The acquisition expands Sanofi’s General Medicines core assets and highlights the addition of Rezurock (belumosudil) to its transplant portfolio.
French biotech Diaccurate bolstered its oncology and immunology pipeline with the acquisition of a Phase II-ready dual PAM inhibitor from Merck KGaA, Darmstadt, Germany.
Scopus Biopharma recently launched Duet Therapeutics to integrate its immunotherapy assets’ management and clinical development with Olimmune.
Swedish Orphan Biovitrum AB (Sobi) has received an $8 billion (68 billion kronor) cash buyout offer from Advent International, valuing its shares at SEK 235 each.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.
The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.
PRESS RELEASES